Back to top

Image: Bigstock

Sanofi (SNY) Presents Positive Diabetes Data on iGlarLixi

Read MoreHide Full Article

Sanofi SNY announced positive results of a new post-hoc analysis of data from a phase III trial that evaluated its investigational candidate, iGlarLixi, a titratable fixed-ratio combination of insulin glargine and lixisenatide.

iGlarLixi was tested for mealtime blood sugar (post-prandial glucose (PPG)) control in adults with type 2 diabetes in the LixiLan-L Trial. The post-hoc analysis of the trial data showed that iGlarLixi led to greater PPG control compared to insulin glargine 100 Units/mL.

The analysis showed that a significantly higher proportion of participants attained the PPG target after 30 weeks. The percentage of patients achieving the PPG target at week 30 was 16.4% higher in the fixed-ratio combination group than the insulin glargine 100 Units/mL arm at 0.5 hour. At one hour and two hours, the proportions of patients achieving the PPG target in the fixed-ratio combination group were 22.4% and 28.2% higher, respectively, compared to the insulin glargine 100 Units/mL arm.

This data was presented at the European Association for the Study of Diabetes’ (EASD) 52nd Annual Meeting in Munich, Germany.

Presently, iGlarLixi is under review in the U.S. and Europe. Sanofi also presented new patient-level meta-analysis data from the EDITION phase III trials in type 2 diabetes at the EASD. Results showed that patients treated with its diabetes drug, Toujeo, demonstrated a consistently lower rate of hypoglycemia compared to its other diabetes drug Lntus(R) at all levels of hba1c (average blood glucose over the previous three months) control.

Zacks Rank & Key Picks

Sanofi currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in health care sector include ANI Pharmaceuticals, Inc. ANIP, Cambrex Corporation CBM and Johnson & Johnson (JNJ - Free Report) . While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Johnson & Johnson (JNJ) - free report >>

Published in